Diabetes & Endocrine Disorders
Gelsey F, Perez-Nieves M, Vass CM, Ling Poon J, Schapiro D, Pierce A, Mansfield C. Preferences of people with type 2 diabetes for features of weekly insulin. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):832. doi: 10.2337/db24-832-P
Johannes CB, Ziemiecki R, Pladevall-Vila M, Kosvesdy CP, Ebert N, Thomsen RWW, Christiansen CF, Baak B, Cabaninas CR, Kashihara N, Yano Y, Kanegae H, Coleman CI, Okami S, Li u F, Layton JB, Vizcaya D, Oberprieler NG. Use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease: a multicountry report from the FOUNTAIN platform. Poster presented at the 2024 ISPE Annual Meeting; August 26, 2024. Berlin, Germany.
Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P. Evidence gap analysis of the burden of disease in thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S389. doi: 10.1016/j.jval.2024.03.2461
Anthony MS, Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B, Beachler DC, Crowe CL, Johannes CB, Juhaeri J, Lanes S, Pan C, Rothman KJ, Saltus CW, Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study. Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
OBJECTIVE: To assess risk of anaphylaxis among patients with type 2 diabetes mellitus initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a focus on those initiating lixisenatide.
Gaudiani L, Sikirica S, Hardin MB, Ervin CM, Goss DS, Kosa KM, Gopinathan S. Patient-reported burden of disease in diabetic peripheral neuropathic pain: learnings from in-depth patient interviews, sub-study of RELIEF-DPN 1. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):484.
Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia-Esteban R, Plana E, Tormos A, Farsani SF, Perez-Gutthann S, Pladevall-Vila M. Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts. Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Oberprieler NG, Pladevall-Vila M, Johannes C, Layton JB, Golozar A, Lavallee M, Liu F, Kubin M, Vizcaya D. FOUNTAIN: a modular research platform for integrated real-world evidence generation. BMC Med Res Methodol. 2024 Oct 1;24(1):224. doi: 10.1186/s12874-024-02344-w
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Oberprieler NG, Kovesdy CP, Layton JB, Gay A, Farjat AE, Liu F, Johannes CB, Pladevall-Vila M, Vizcaya D. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis. Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
BACKGROUND: Based on evidence from clinical trials, finerenone reduces the risk of cardiovascular and renal complications among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence from finerenone use in real-world clinical practice is lacking.